jack14 Posted February 13, 2021 Share Posted February 13, 2021 I have been advised that although the use of Crizotinib has only been approved by the FDA for the MET 14 mutation, that it has been used for MET amplification with some success in trials. My Oncologist says that although I have that marker, and it's the only one that has any potential for targeting at this time, she isn't confident that the VA will approve it. I will know Monday if the Keytruda isn't working anymore and we may be looking at this, or chemo as our next line of therapy. I have also been advised by a represenative at GO2 Foundation that one can develop targetable mutations that were not identified before a course of treatment was administered. I am not sure that the VA or Medicare would approve of a second genetic assessment or not. But if they did, can they use my blood to get an updated panel of genes from rather than having to excise or aspirate another lymph node specimen? Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.